Hormonal
Metabolic syndrome is NOT associated with a higher risk of myocardial infarction or stroke, although individual components like elevated blood pressure, reduced HDL, and elevated triglycerides are.
Having metabolic syndrome does not necessarily increase your risk of heart attack or stroke, but managing individual components like high blood pressure, low HDL cholesterol, and high triglycerides does reduce this risk. Focus on controlling these specific markers.
MetS... was neither associated with higher risk of myocardial infarction nor stroke... elevated blood pressure, reduced HDL-cholesterol, and elevated triglycerides were associated with higher risk of major cardiovascular event.
Why this rating
Robust prospective data, but the negative finding for MI/stroke contrasts with some meta-analyses, requiring careful interpretation.
Source
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort
María Jesús Guembe et al. · Cardiovascular Diabetology · 2020
DOI 10.1186/s12933-020-01166-6
More from this paper
- Metabolic syndrome (MetS) is independently associated with a higher risk of major cardiovascular events, cardiovascular mortality, and all-cause mortality, advancing the onset of these risks by approximately 3.2 years.Good
- The number of metabolic syndrome traits (0-5) is positively associated with the incidence of major cardiovascular events, with each additional trait increasing the risk by 22%.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →